BRAVO: Background Regimen of Raltegravir on Virologic Outcome
Outcomes of Early Raltegravir Experience: Comparison of Virologic Response in Regimens Not Containing a Protease Inhibitor in the Antiretroviral Background Regimen Versus a Protease Inhibitor in the Background Regimen
Sponsor: Community Research Initiative of New England
This observational or N/A phase trial investigates HIV Infections and is currently completed. Community Research Initiative of New England leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Mar 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Community Research Initiative of New England
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Boston, United States, Buffalo, United States, Chicago, United States, Dallas, United States, Glastonbury, United States, Los Angeles, United States, New York, United States, Orlando, United States, Philadelphia, United States, San Francisco, United States and 2 more location s